Section Arrow
Quote
CNSP.NASDAQ
- CNS Pharmaceuticals Inc.
Quotes are at least 15-min delayed:2025/05/29 00:52 EDT
Last
 1.05
-0.03 (-2.78%)
Day High 
1.1 
Prev. Close
1.08 
1-M High
2.8999 
Volume 
260.91K 
Bid
1.07
Ask
1.1
Day Low
1.05 
Open
1.06 
1-M Low
0.988 
Market Cap 
5.90M 
Currency USD 
P/E 0 
%Yield -- 
10-SMA 1.22 
20-SMA 1.16 
50-SMA 1.44 
52-W High 637.25 
52-W Low 0.0835 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-924.60/-1.15
Enterprise Value
5.90M
Balance Sheet
Book Value Per Share
2.01
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.7064+0.4689+197.43%-- 
SPROSpero Therapeutics2.35+1.668+244.57%9.58PE
NCNANuCana plc0.0375-0.0015-3.85%-- 
PLRZPolyrizon Ltd1.03+0.384+59.44%-- 
VERUVeru0.5286+0.0196+3.85%-- 
Quotes are at least 15-min delayed：2025/05/29 00:52 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.